Posts by FLARE Team, Mass General
-
Do Adenovirus Vaccines Cause Clotting?
Many people are asking...do adenovirus vaccines cause clotting?
-
Are The Two Newly Authorized COVID-19 Vaccines Safe and Effective?
The FDA issued an EUA for two vaccine candidates from Pfizer-BioNTech and Moderna. Both vaccines report an efficacy of around 95% across different age groups, sex, ethnicity, and comorbidity risk status, which is extremely encouraging as COVID-19 cases in the US continue to climb.
-
COVID-19 Vaccine Candidates
The effort to produce and distribute a SARS-CoV-2 vaccine has made remarkable progress. Currently there are over 180 candidate vaccines against SARS-CoV-2 in development worldwide.
-
What Is a Superspreader Event?
The primary mode of transmission of SARS-Cov-2 is close contact between persons. Accordingly, there has been a heavy emphasis on effective non-pharmaceutical interventions. Breakdowns in physical distancing and gatherings have been associated with significant numbers of infections.
-
What We Have Learned About COVID-19: Part One
Since the initial outbreak of COVID-19, clinicians have treated hundreds of thousands of patients. At the same time, over 55,000 COVID-related research articles have been published (albeit of heterogeneous quality). There is now substantial consensus on optimal treatment of the critically ill patient with COVID-19.
-
Expedited Publication in the Era of COVID-19
An unprecedented volume of academic literature has been produced since the start of the COVID-19 pandemic. Lessons may be learned from the expedited publication approach.
-
Cardiac Arrest and COVID-19
In-hospital cardiac arrest (IHCA) during the COVID-19 pandemic presents a unique set of resuscitation challenges such as exposure risk to clinical providers and obstacles to family communication. In this FLARE, we provide a brief review of IHCA in the pre-COVID-19 era and then discuss emerging evidence regarding IHCA during the COVID-19 pandemic.
-
RV Failure in COVID-19
In this FLARE, we review the epidemiology and pathophysiology of critical illness-associated RV dysfunction to inform the management of patients suffering from severe COVID-19.
-
Pediatric Multisystem Inflammatory Syndrome and COVID-19
Initial reports from China indicated that COVID-19 largely spared pediatric patients (Liu et al. 2020; Dong et al. 2020), while early reports from the US and Europe indicated that < 5% of symptomatic cases were in children and the number of deaths was vanishingly small (CDC MMWR 2020; Docherty et al. 2020).
-
Survivors of Critical Illness in COVID-19
Many people are saying ... we need to understand and address the long-term outcomes of COVID-19 ICU survivors.
-
What Causes Hypoxemia in COVID-19? (Part II)
Many people are saying...hypoxemia in COVID-19 is something entirely new.
-
What Causes Hypoxemia in COVID-19? (Part I)
Many people are saying...hypoxemia in COVID-19 is something entirely new.
-
Pets and COVID-19
Many people are wondering...can my pet get COVID-19? There have been reports of captive animals contracting SARS-CoV-2 with differing levels of severity, raising suspicion for human-to-animal transmission.
-
The second to last HCQ trial?
Initial interest in the use of hydroxychloroquine for the treatment of COVID-19 was spurred by a somewhat plausible mechanism of action and a small study which has since been widely criticized.
-
Can a CT tell you how to ventilate in COVID-19?
Many people are still saying...COVID-19 patients have unique respiratory failure phenotypes.
-
Mechanical Ventilation in the Era of COVID-19: An Ongoing Debate
Coronavirus 2019 (COVID-19) has created much debate in the critical care world regarding a slew of management decisions, including sedation, proning, and mechanical ventilation strategies. To date, much of this debate has been limited to anecdotal experiences and case series.
-
New Observational Reports on Anticoagulation and Immunomodulation
Many people are saying...several drugs show promise in COVID-19.
-
New Data on Protective Immunity After COVID-19
The world is eager for an “immunity test” for SARS-CoV-2, but the level and duration of protective immunity after recovery from COVID-19 remain to be defined.
-
Superinfection in COVID-19
Although SARS-CoV-2 infection is responsible for COVID-19, it remains unclear whether viral-induced cell death per se is ultimately fully responsible for the clinical syndrome following infection.
-
Protective Immunity to SARS-CoV-2
Evidence suggests that humans will develop protective immunity after infection with SARS-CoV-2, although immunity may wane with time.
-
Of Ventilators and the Undiscovered Country
Many people are saying...mortality among intubated patients with COVID-19 is exceedingly high.
-
Pregnancy and SARS-CoV-2 infection
Many people are worrying...that pregnant women are more likely to have poor outcomes from SARS-CoV-2 infection.
-
Viral Load in COVID-19
Many people are asking...is severe COVID-19 due to the virus or the immune response?
-
Use of Convalescent Plasma
Today's FLARE will investigate the rationale and evidence for utilizing convalescent plasma in COVID-19.
-
PEEP, ARDS and COVID-19 Associated Respiratory Failure
Today's FLARE email deals extensively with PEEP and the appropriate way to set it in ARDS in general and COVID-19 associated respiratory failure.
-
Additional Therapeutics for SARS-CoV-2
Today's FLARE focus will be on additional therapeutics for SARS-CoV-2.
Biography
Mass General FLARE is a collaborative effort within the Pulmonary and Critical Care Division and the Department of Medicine. Its mission is to appraise the rapidly evolving literature on SARS-CoV-2 with a focus on critical care issues.
Core members include:
